Enanta Pharmaceuticals (NASDAQ:ENTA) Announces Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Enanta Pharmaceuticals (NASDAQ:ENTA – Get Rating) released its quarterly earnings results on Monday. The biotechnology company reported ($1.63) EPS for the quarter, missing analysts’ consensus estimates of ($1.43) by ($0.20), MarketWatch Earnings reports. Enanta Pharmaceuticals had a negative return on equity of 24.62% and a negative net margin of 108.39%. During the same quarter in the previous year, the firm posted ($1.09) earnings per share.

Shares of ENTA opened at $52.93 on Tuesday. The firm has a market cap of $1.09 billion, a price-to-earnings ratio of -10.63 and a beta of 0.64. Enanta Pharmaceuticals has a fifty-two week low of $40.37 and a fifty-two week high of $102.00. The firm has a 50 day moving average price of $68.63 and a 200-day moving average price of $71.77.

In related news, Director Bruce L. A. Carter sold 6,000 shares of the company’s stock in a transaction on Monday, March 21st. The shares were sold at an average price of $67.83, for a total transaction of $406,980.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, VP Nathalie Adda sold 50,559 shares of the company’s stock in a transaction on Friday, April 1st. The shares were sold at an average price of $71.23, for a total transaction of $3,601,317.57. Following the sale, the vice president now owns 34,982 shares of the company’s stock, valued at $2,491,767.86. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 113,683 shares of company stock valued at $8,084,777. Company insiders own 12.42% of the company’s stock.

A number of large investors have recently bought and sold shares of ENTA. Royal Bank of Canada raised its holdings in Enanta Pharmaceuticals by 1,367.7% in the 2nd quarter. Royal Bank of Canada now owns 1,409 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 1,313 shares in the last quarter. Schonfeld Strategic Advisors LLC bought a new position in Enanta Pharmaceuticals in the 4th quarter worth $426,000. Marshall Wace LLP bought a new position in Enanta Pharmaceuticals in the 4th quarter worth $723,000. Public Employees Retirement System of Ohio raised its holdings in Enanta Pharmaceuticals by 153.4% in the 4th quarter. Public Employees Retirement System of Ohio now owns 10,945 shares of the biotechnology company’s stock worth $818,000 after purchasing an additional 6,625 shares in the last quarter. Finally, Wells Fargo & Company MN raised its holdings in Enanta Pharmaceuticals by 392.4% in the 2nd quarter. Wells Fargo & Company MN now owns 20,665 shares of the biotechnology company’s stock worth $910,000 after purchasing an additional 16,468 shares in the last quarter. Institutional investors own 98.87% of the company’s stock.

ENTA has been the subject of a number of research reports. SVB Leerink cut their price target on shares of Enanta Pharmaceuticals from $80.00 to $68.00 and set a “market perform” rating for the company in a research note on Wednesday, February 9th. Zacks Investment Research raised shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 18th. JMP Securities reissued a “buy” rating and issued a $116.00 price target on shares of Enanta Pharmaceuticals in a research note on Wednesday, March 30th. Finally, StockNews.com initiated coverage on shares of Enanta Pharmaceuticals in a research note on Thursday, March 31st. They issued a “hold” rating for the company. Five analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. According to MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Hold” and an average target price of $91.75.

About Enanta Pharmaceuticals (Get Rating)

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus.

Featured Articles